Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IchthoBad is a medicinal bath additive developed by Ichthyol-Gesellschaft Cordes Hermanni & Co, containing light sodium bituminosulfonate (Ichthyol sodium) as its active pharmaceutical ingredient. It is indicated for the supportive treatment of subacute and chronic inflammatory skin diseases, including psoriasis, various forms of eczema, and pruritus (itching). Sodium bituminosulfonate is derived from the distillation of sulfur-rich oil shale and subsequent sulfonation. It exerts anti-inflammatory, anti-pruritic, and mild antimicrobial effects, which help alleviate skin irritation, reduce redness, and promote healing when applied topically through full or partial baths.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium bituminosulfonate.